Safety and Efficacy of IBI306 in Chinese Subjects With Non-familial Hypercholesterolemia
Phase 3
Completed
- Conditions
- Hypercholesterolemia
- Interventions
- Drug: IBI306 600mg SC Q6WOther: Placebo SC Q6WDrug: IBI306 450mg SC Q4WDrug: Placebo SC Q4W
- First Posted Date
- 2020-02-28
- Last Posted Date
- 2022-04-11
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 804
- Registration Number
- NCT04289285
- Locations
- 🇨🇳
Peking University First Hospital, Beijing, China
The Study of IBI310 in Combination With IBI308 Compared to High-Dose Interferon In Patients With Acral Melanoma That Has Been Removed by Surgery
Phase 3
Terminated
- Conditions
- Acral Melanoma That Has Been Removed by Surgery
- Interventions
- First Posted Date
- 2020-02-20
- Last Posted Date
- 2023-03-09
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 136
- Registration Number
- NCT04277663
- Locations
- 🇨🇳
Beijing cancer hospital, Beijing, China
IBI310 in Combination with Sintilimab in Patients with DNA Mismatch Repair Deficient (dMMR)/microsatellite Instability High (MSI-H) Locally-advanced or Metastatic Colorectal Cancer
Phase 2
Terminated
- Conditions
- Colorectal Cancer
- Interventions
- Biological: IBI310 (anti-CTLA-4 antibody)Biological: Sintilimab(anti-PD-1 antibody)
- First Posted Date
- 2020-02-06
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 4
- Registration Number
- NCT04258111
- Locations
- 🇨🇳
Beijing cancer hospital, Beijing, China
Phase 1 Study of Pemigatinib in Patients With Advanced Malignancies With FGF/FGFR Alterations
- First Posted Date
- 2020-02-06
- Last Posted Date
- 2021-07-23
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 12
- Registration Number
- NCT04258527
- Locations
- 🇨🇳
Cancer Hospital of Tianjin Medical University, Tianjin, China
Pemigatinib in Treating Patients With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Rearrangement
- First Posted Date
- 2020-02-05
- Last Posted Date
- 2024-05-30
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 34
- Registration Number
- NCT04256980
- Locations
- 🇨🇳
Zhongshan Hospital Affiliated to Fudan University, Shanghai, Shanghai, China
Intense Monitoring Study on Tyvyt
Recruiting
- Conditions
- Relapsed or Refractory Classical Hodgkin's Lymphoma
- First Posted Date
- 2020-01-23
- Last Posted Date
- 2022-09-16
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 300
- Registration Number
- NCT04237233
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, China
A Study of IBI377 in Combination With Corticosteroids for the Treatment of First-Line Acute Graft-Versus-Host Disease
Phase 1
Terminated
- Conditions
- GVHD,Acute
- Interventions
- First Posted Date
- 2020-01-07
- Last Posted Date
- 2020-10-29
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 1
- Registration Number
- NCT04220632
- Locations
- 🇨🇳
The First Affiliated Hospital of Suzhou University, Suzhou, Jiangsu, China
Safety and Efficacy of IBI306 in HeFH Patients
Phase 3
Completed
- Conditions
- Heterozygous Familial Hypercholesterolemia
- Interventions
- Drug: placebo
- First Posted Date
- 2019-11-27
- Last Posted Date
- 2023-08-09
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 149
- Registration Number
- NCT04179669
- Locations
- 🇨🇳
Beijing Anzhen Hospital, Capital Medical University, Beijing, China
A PK Similarity Study of Two Sintilimab Products Produced by Different Processes in Advanced or Metastatic NSCLC Patients
Phase 1
Completed
- Conditions
- Advanced or Metastatic NSCLC
- Interventions
- First Posted Date
- 2019-11-26
- Last Posted Date
- 2023-02-27
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT04177290
- Locations
- 🇨🇳
The First Affiliated Hospital of Bengbu Medical College, Bengbu, China
A Phase Ia/Ib Study of IBI315 in Patients With HER2-expressing Advanced Solid Tumor
- First Posted Date
- 2019-11-14
- Last Posted Date
- 2023-10-24
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 55
- Registration Number
- NCT04162327
- Locations
- 🇨🇳
The 307th Hospital of Chinese People's Liberation Army, Beijing, China
© Copyright 2025. All Rights Reserved by MedPath